Apalutamide manufacturers and suppliers in india

Apalutamide

CAS:: 956104-40-8

MF:: C21H15F4N5O2S

MW:: 477.43

Suppliers by country/region

Company Type

Properties

Density: 1.59±0.1 g/cm3(Predicted)

storage temp.: Store at -20°C

solubility: ≥23.85 mg/mL in DMSO; insoluble in H2O; ≥7.33 mg/mL in EtOH

form: solid

pka: 13.83±0.46(Predicted)

color: White to off-white

InChI: InChI=1S/C21H15F4N5O2S/c1-27-17(31)13-4-3-11(8-15(13)22)30-19(33)29(18(32)20(30)5-2-6-20)12-7-14(21(23,24)25)16(9-26)28-10-12/h3-4,7-8,10H,2,5-6H2,1H3,(H,27,31)

InChIKey: HJBWBFZLDZWPHF-UHFFFAOYSA-N

SMILES: C(NC)(=O)C1=CC=C(N2C(=S)N(C3=CC(C(F)(F)F)=C(C#N)N=C3)C(=O)C32CCC3)C=C1F

Safety Information

Symbol(GHS): GHS07

Signal word: Warning

Hazard statements: H302

Precautionary statements: P280-P305+P351+P338

Use

ARN-509 (10 mg/kg/d, oral) inhibits tumor growth with decreased proliferative index and increased apoptotic rate in castrate male immunodeficient mice harboring LNCaP/AR-luc xenograft tumors. ARN-509 dose dependently inhibits tumor growth with highest efficacy at dose of 30 mg/kg/day in castrate male immunodeficient mice harboring LNCaP/AR-luc xenograft tumors. ARN-509 dosed at 10 mg/kg/d for 28 days results in a 3-fold reduction in prostates weight associated with lacking glandular secretory activity and 1.7-fold reduction in epididymis weight in adult male dogs. ARN-509 (10 mg/kg/d, oral) inhibits cell proliferation of prostate tissues in adult male dogs. ARN-509 is safe and well tolerated in 24 patients with metastatic CRPC who has progressed on prior treatments and peak plasma concentrations occurred 2 to 3 hours after administration. ARN-509 results in durable PSA declines at doses ranging from 30 to 300 mg in patients with metastatic CRPC. ARN-509 shows powerful anti-cancer activity and induces durable remissions long after therapy completion in castrate resistant prostate cancer mouse models.